Department of Radiation Oncology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):86-91. doi: 10.1016/j.ijrobp.2009.04.018. Epub 2009 Jul 23.
To evaluate the outcomes of patients with localized orbital marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) who were treated with radiotherapy (RT).
We retrospectively reviewed the records of 46 patients who were treated with RT for pathologically confirmed localized stage IE marginal zone B-cell lymphoma of MALT. The radiation dose ranged from 21.6 to 45 Gy (median, 30.6 Gy) at 1.8-2.0 Gy per fraction. Median follow-up duration was 32.3 months (range, 3.1-113.6 months).
Forty-three patients (93%) achieved complete remission (CR), and three patients (7%) achieved partial remission (PR). Five-year relapse-free survival, cause-specific survival, and overall survival were 93%, 100%, and 100%, respectively. Among the patients with CR, two had recurrence at three sites. One patient relapsed locally and was successfully salvaged with reirradiation. The other patient relapsed in a distant site and was successfully treated with six cycles of CHOP chemotherapy. Late complications were noted in four patients. Two patients developed cataracts at 26 and 37 months after completion of RT. The other two patients developed nasolacrimal duct obstructions at 4 and 11 months after completion of RT.
Our study showed that a modest dose of RT is an excellent treatment modality with low complication and recurrence rates. We suggest that a dose of 30.6 Gy is tolerable and sufficient for treating orbital MALT lymphoma. Even following recurrence, successful salvage is possible with RT or chemotherapy.
评估接受放射治疗（RT）的黏膜相关淋巴组织（MALT）局限性眶边缘区 B 细胞淋巴瘤（MALT 淋巴瘤）患者的治疗结果。
我们回顾性分析了 46 例经病理证实为局限性 IE 期 MALT 边缘区 B 细胞淋巴瘤患者接受 RT 治疗的记录。放射剂量范围为 21.6 至 45 Gy（中位数，30.6 Gy），每次分割 1.8-2.0 Gy。中位随访时间为 32.3 个月（范围，3.1-113.6 个月）。
43 例（93%）患者达到完全缓解（CR），3 例（7%）患者达到部分缓解（PR）。5 年无复发生存率、无病生存率和总生存率分别为 93%、100%和 100%。在 CR 患者中，2 例患者在 3 个部位复发。1 例患者局部复发，经再放疗成功挽救。另 1 例患者远处部位复发，经 6 个周期 CHOP 化疗成功治疗。4 例患者出现晚期并发症。2 例患者在 RT 完成后 26 个月和 37 个月时发生白内障。另外 2 例患者在 RT 完成后 4 个月和 11 个月时发生鼻泪管阻塞。
我们的研究表明，适度剂量的 RT 是一种具有低并发症和复发率的优秀治疗方法。我们建议 30.6 Gy 的剂量是治疗眼眶 MALT 淋巴瘤的可耐受且足够的剂量。即使复发，RT 或化疗也可成功挽救。
